Jack Whitaker, MD
Cardiovascular Disease · Greeneville, TNNPI 1922064047
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,850 of the $74,923 with a category attached, or 71.9%. 37 manufacturers reported payments, led by AstraZeneca at 32.5% of the total. Reporting peaked in 2019 at $40,363 and has fallen 97.3% since, to $1,108 in 2025. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 656 payments — averaging $114.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Boehringer Ingelheim$19K
- Lilly USA, LLC$18K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
- Medtronic$1K
- Novartis$1K
- plus $7K from 31 others
Across 190 payments — averaging $1742.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$205K
- Esperion Therapeutics, Inc.$63K
- Janssen Research & Development, LLC$33K
- Kowa Research Institute, Inc.$15K
- Sanofi US Services Inc.$11K
- Novo Nordisk AS$3K
What the payments were for
- Consulting fees$5,3807%
- Speaking & faculty fees$53,85072%
- Travel & lodging$4,2126%
- Food & beverage$11,36515%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 94 | $24,325 |
| Boehringer Ingelheim | 71 | $19,032 |
| Lilly USA, LLC | 24 | $17,871 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 99 | $4,396 |
| Medtronic(2 entities) | 10 | $1,318 |
| Novartis | 131 | $1,219 |
| Janssen Research & Development, LLC | 8 | $968 |
| Heartflow, Inc. | 9 | $813 |
| Abbott | 27 | $760 |
| Johnson & Johnson | 40 | $654 |
| Esperion Therapeutics, Inc. | 25 | $633 |
| Amgen | 23 | $445 |
| Abiomed | 4 | $433 |
| E.r. Squibb & Sons, L.L.C. | 12 | $259 |
| Novo Nordisk | 5 | $242 |
| Merck | 13 | $228 |
| Cvrx, Inc. | 1 | $192 |
| Pfizer | 10 | $186 |
| Atricure, Inc. | 3 | $148 |
| Lexicon Pharmaceuticals, Inc. | 8 | $145 |
| Sanofi-aventis U.S. LLC | 7 | $113 |
| Akcea Therapeutics, Inc. | 4 | $76 |
| Portola Pharmaceuticals, LLC | 4 | $60 |
| Irhythm Technologies, Inc. | 3 | $57 |
| Edwards Lifesciences | 3 | $53 |
| Elutia, Inc. | 3 | $51 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Boston Scientific | 2 | $35 |
| Bayer | 2 | $32 |
| Lundbeck LLC | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Philips North America LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Celonova Biosciences, Inc. | 1 | $11 |
| Convatec Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,923 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $201,460 |
| XareltoRivaroxaban | 64 | $43,663 |
| EntrestoSacubitril/Valsartan | 42 | $42,198 |
| BrilintaTicagrelor | 36 | $23,988 |
| OzempicSemaglutide | 13 | $16,894 |
| JardianceEmpagliflozin | 16 | $16,625 |
| FarxigaDapagliflozin Propanediol | 12 | $10,073 |
| Repatha SureclickEvolocumab | 12 | $6,489 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $6,066 |
| Famotidine | 201 | $2,628 |
| Rosuvastatin Calcium | 183 | $2,349 |
| Atorvastatin Calcium | 196 | $1,881 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 58 | $1,396 |
| Metoprolol Succinate | 127 | $1,259 |
| ClopidogrelClopidogrel Bisulfate | 119 | $1,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $186 | $201,460196 claims |
| Johnson & JohnsonXarelto | $654 | $43,66364 claims |
| NovartisEntresto | $1,219 | $42,19842 claims |
| AstraZenecaBrilinta, Farxiga | $24,325 | $34,06148 claims |
| Novo NordiskOzempic | $242 | $16,89413 claims |
| Boehringer IngelheimJardiance | $19,032 | $16,62516 claims |
| Esperion Therapeutics, Inc.Nexlizet | $633 | $6,06611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Greeneville
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- Selcuk TombulChattanooga$198K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.